Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2011 1
2018 1
2019 3
2020 7
2021 6
2022 7
2023 5
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

31 results

Results by year

Filters applied: . Clear all
Page 1
Sotigalimab and/or nivolumab with chemotherapy in first-line metastatic pancreatic cancer: clinical and immunologic analyses from the randomized phase 2 PRINCE trial.
Padrón LJ, Maurer DM, O'Hara MH, O'Reilly EM, Wolff RA, Wainberg ZA, Ko AH, Fisher G, Rahma O, Lyman JP, Cabanski CR, Yu JX, Pfeiffer SM, Spasic M, Xu J, Gherardini PF, Karakunnel J, Mick R, Alanio C, Byrne KT, Hollmann TJ, Moore JS, Jones DD, Tognetti M, Chen RO, Yang X, Salvador L, Wherry EJ, Dugan U, O'Donnell-Tormey J, Butterfield LH, Hubbard-Lucey VM, Ibrahim R, Fairchild J, Bucktrout S, LaVallee TM, Vonderheide RH. Padrón LJ, et al. Among authors: yu jx. Nat Med. 2022 Jun;28(6):1167-1177. doi: 10.1038/s41591-022-01829-9. Epub 2022 Jun 3. Nat Med. 2022. PMID: 35662283 Free PMC article. Clinical Trial.
Combinations take centre stage in PD1/PDL1 inhibitor clinical trials.
Upadhaya S, Neftelino ST, Hodge JP, Oliva C, Campbell JR, Yu JX. Upadhaya S, et al. Among authors: yu jx. Nat Rev Drug Discov. 2021 Mar;20(3):168-169. doi: 10.1038/d41573-020-00204-y. Nat Rev Drug Discov. 2021. PMID: 33177720 Review. No abstract available.
Surgical management of pituitary adenoma during pregnancy.
Jia XY, Guo XP, Yao Y, Deng K, Lian W, Xing B. Jia XY, et al. World J Clin Cases. 2023 Apr 26;11(12):2694-2707. doi: 10.12998/wjcc.v11.i12.2694. World J Clin Cases. 2023. PMID: 37214566 Free PMC article.
Immuno-oncology drug development goes global.
Xin Yu J, Hubbard-Lucey VM, Tang J. Xin Yu J, et al. Nat Rev Drug Discov. 2019 Nov;18(12):899-900. doi: 10.1038/d41573-019-00167-9. Nat Rev Drug Discov. 2019. PMID: 31780841 No abstract available.
The clinical pipeline for cancer cell therapies.
Upadhaya S, Yu JX, Shah M, Correa D, Partridge T, Campbell J. Upadhaya S, et al. Among authors: yu jx. Nat Rev Drug Discov. 2021 Jul;20(7):503-504. doi: 10.1038/d41573-021-00100-z. Nat Rev Drug Discov. 2021. PMID: 34088999 No abstract available.
Cancer cell therapies: the clinical trial landscape.
Yu JX, Upadhaya S, Tatake R, Barkalow F, Hubbard-Lucey VM. Yu JX, et al. Nat Rev Drug Discov. 2020 Sep;19(9):583-584. doi: 10.1038/d41573-020-00099-9. Nat Rev Drug Discov. 2020. PMID: 32457476 No abstract available.
Impact of COVID-19 on oncology clinical trials.
Upadhaya S, Yu JX, Oliva C, Hooton M, Hodge J, Hubbard-Lucey VM. Upadhaya S, et al. Among authors: yu jx. Nat Rev Drug Discov. 2020 Jun;19(6):376-377. doi: 10.1038/d41573-020-00093-1. Nat Rev Drug Discov. 2020. PMID: 32424343 No abstract available.
Immuno-oncology drug development forges on despite COVID-19.
Upadhaya S, Hubbard-Lucey VM, Yu JX. Upadhaya S, et al. Among authors: yu jx. Nat Rev Drug Discov. 2020 Nov;19(11):751-752. doi: 10.1038/d41573-020-00166-1. Nat Rev Drug Discov. 2020. PMID: 32948858 No abstract available.
31 results